Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial

Key Takeaways for GI Nurses

• The SCREESCO trial provides important comparative data on colonoscopy versus fecal immunochemical testing (FIT) for colorectal cancer screening, informing evidence-based patient education and screening program protocols
• Understanding the relative effectiveness of these screening modalities helps nurses guide patient decision-making and address common concerns about screening options during pre-procedure consultations
• Results may influence institutional screening protocols and workflow planning, potentially affecting colonoscopy volumes and resource allocation in endoscopy units
• The trial reinforces the importance of systematic screening approaches and supports nurses' role in promoting adherence to established colorectal cancer screening guidelines

Clinical Relevance

This randomized controlled trial has significant implications for endoscopy nursing practice, particularly in patient education and screening program coordination. As frontline healthcare providers, GI nurses frequently encounter patients who are uncertain about which screening method to choose or who express anxiety about colonoscopy procedures. Having robust comparative data from a well-designed trial like SCREESCO enables nurses to provide evidence-based counseling that addresses patient concerns while supporting informed decision-making. This is especially valuable when discussing the trade-offs between the convenience and non-invasiveness of FIT testing versus the comprehensive diagnostic and therapeutic capabilities of colonoscopy.

From an operational perspective, the trial findings may influence how endoscopy units structure their screening programs and allocate resources. If the data demonstrates comparable effectiveness between screening modalities for certain patient populations, this could lead to more strategic use of colonoscopy capacity, potentially reducing wait times for high-risk patients while maintaining effective population-level screening. GI nurses involved in quality improvement initiatives and program development will need to consider these findings when evaluating current protocols and planning future screening strategies.

The trial also underscores the evolving landscape of colorectal cancer screening and the importance of staying current with research evidence. For endoscopy nurses pursuing professional development or advanced practice roles, understanding comparative effectiveness research helps build expertise in screening program management and population health approaches. This knowledge is increasingly valuable as healthcare systems focus on optimizing screening uptake and outcomes while managing costs and resource utilization.

Bottom Line

The SCREESCO trial provides critical evidence comparing colonoscopy and FIT testing that will help GI nurses deliver more informed patient education, support evidence-based screening decisions, and contribute to optimized screening program protocols - ultimately enhancing our ability to reduce colorectal cancer mortality through effective, patient-centered screening approaches.